Tigecycline

Tigecycline is the first commercially available antibiotic of the glycylcycline class, which are a new family based on tetracyclines, but with molecular modifications to evade some, but not all, tetracycline resistance mechanisms. ^[1] Tetracycline resistance... ^[2]

Its labeled indications are:^[3]

Complicated Appendicitis
Complicated Bacterial Peritonitis
Complicated Skin and Skin Structure Infection
Complicated Skin and Skin Structure E. Coli Infection
Complicated Skin and Skin Structure Enterococcus faecalis Infection,

Complicated Skin and Skin Structure Staphylococcus aureus Infection
Complicated Skin and Skin Structure Streptococcus agalactiae Infection
Complicated Skin and Skin Structure Streptococcus pyogenes Infection
Haemophilus influenzae Pneumonia,

Infectious Disease of Abdomen
Intra-Abdominal Abscess*
Legionella pneumophila Pneumonia
Streptococcal Pneumonia

Mechanism of action

The drug evades the Tet(A-E) efflux pumps^[4] which account for most acquired resistance to tetracycline and minocycline in Enterobacteriaceae and Acinetobacter spp.; also the Tet(K) pumps, which occur widely in staphylococci conferring resistance to tetracycline though not minocycline or doxycycline.^[2] It binds to bacterial ribosomes that have been modified by the Tet(M) protein,Cite error: Closing </ref> missing for <ref> tag

References

↑ David M. Livermore (2005), "Tigecycline: what is it, and where should it be used?", Journal of Antimicrobial Chemotherapy 56 (4): 611-614, DOI:10.1093/jac/dki291
↑ ^2.0 ^2.1 Chopra I (1986), "Genetic and biochemical basis of tetracycline resistance", J Antimicrob Chemother 18 (Suppl C): 51–6
↑ Tigecycline IV, American Society of Health-System Pharmacists
↑ Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738–44

[1] David M. Livermore (2005), "Tigecycline: what is it, and where should it be used?", Journal of Antimicrobial Chemotherapy 56 (4): 611-614, DOI:10.1093/jac/dki291

[Chopra-2] 2.0 ^2.1 Chopra I (1986), "Genetic and biochemical basis of tetracycline resistance", J Antimicrob Chemother 18 (Suppl C): 51–6

[3] Tigecycline IV, American Society of Health-System Pharmacists

[Petersen-4] Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738–44

[1]

[2]

[3]

[4]

Tigecycline

Mechanism of action

References

Navigation menu

Search